Help
RSS
API
Feed
Maltego
Contact
Domain > www.ioteachwithmehcp.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2021-07-20
13.226.186.124
(
ClassC
)
2025-01-14
45.60.150.161
(
ClassC
)
Port 80
HTTP/1.1 301 Moved PermanentlyServer: CloudFrontDate: Thu, 10 Oct 2024 11:07:25 GMTContent-Type: text/htmlContent-Length: 167Connection: keep-aliveLocation: https://www.ioteachwithmehcp.com/X-Cache: R html>head>title>301 Moved Permanently/title>/head>body>center>h1>301 Moved Permanently/h1>/center>hr>center>CloudFront/center>/body>/html>
Port 443
HTTP/1.1 200 OKContent-Type: text/html;charsetutf-8Transfer-Encoding: chunkedConnection: keep-aliveDate: Thu, 10 Oct 2024 11:07:25 GMTServer: ApacheX-Content-Type-Options: nosniffAccept-Ranges: bytesX !DOCTYPE HTML>html langen> head> meta nameviewport contentwidthdevice-width, initial-scale1.0/> meta charsetUTF-8/>!--/ Commercial Code integration starts here/--> meta namekeywords/> title>Home/title> script> var digitalData { friendly_name : opdivo-yervoy-hcp-us-en-branded, // Friendly Site Name (brand + dtc/hcp + country + language + branded/unbranded) brand_name : Opdivo, Opdivo + Yervoy, // Brand of Site (prop7) user_type : HCP, // hcp, dtc (prop10) site_country : US, // Country of Site (prop12) site_language : English, // Language of Site (prop13) site_type : Branded, // Branded/unbranded franchise_name: Immuno-Oncology, // What Franchise is this under (prop8) indication : All indications, // Indication of site site_abbreviation: IOTeachWithMeHCP-com-hcp-us // prop18 domain of the site + dtc/hcp + country }/script>script typeapplication/ld+json> { @context: http://schema.org, @type: Brand, name: OPDIVO® + YERVOY®, logo: https://www.opdivo.com/content/dam/commercial/us/opdivodtc/en/image/OPDIVO-logo.svg, url: https://www.opdivo.com/advanced-nsclc-combination, alternateName: nivolumab and ipilimumab, description: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) is used as a first-line advanced non-small cell lung cancer treatment option for certain people whose tumors are positive for PD-L1. Please see Indication and Important Safety Information. }, { @context: http://schema.org, @type: Drug, activeIngredient: nivolumab and ipilimumab, administrationRoute: intravenous (IV) infusion, drugClass: monoclonal antibody , dosageForm: infusion, name: OPDIVO® + YERVOY®, url: https://www.opdivo.com/advanced-nsclc-combination, nonProprietaryName: nivolumab and ipilimumab, alternateName: nivolumab and ipilimumab, description: OPDIVO® (nivolumab) + YERVOY® (ipilimumab) is used as a first-l
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]